Tatva Chintan reports strong Q2 FY26 revenue and EBITDA growth

For the second quarter of financial year 2026, Tatva Chintan Pharma Chem Limited reported operating revenue of INR1,235 million, marking a 48% year-on-year growth and a 6% sequential increase. EBITDA stood at INR222 million, reflecting a substantial 298% growth year-on-year and a 28% improvement over the previous quarter, attributed to an improved product mix and better operating leverage.

Segment-wise, Structure Directing Agents (SDA) reported INR593 million in revenue, a 51% quarter-on-quarter growth and a 119% year-on-year increase. Phase Transfer Catalysts (PTC) contributed INR293 million, showing a 1% growth quarter-on-quarter and 7% year-on-year. Pharma, Agro and Specialty Chemicals delivered INR324 million in revenue, down 31% sequentially but growing 19% year-on-year. Electrolyte Salts achieved INR12 million in revenue, recording a 47% sequential growth.

The company anticipates continued growth, with new agro products expected to contribute significantly, potentially reaching INR300 crores to INR350 crores at full scale. Commercialization of new pharma products is scheduled from December 2025 to the second half of 2026. The new plant block is on schedule to be available for commercial production from January 2026, aiming to optimize production and achieve desired volumes efficiently.